Genmab — September 2013
-
-
Jeg ved godt, at vi lige har fået et godbid af karat - men er det ikke snart på tide at vi hører lyden af det liflige vacuum-POP!, det giver, når Janssen langt om længe trækker fingeren ud af den tætsluttende muskel i rektum og trykker sæt-igang på Dara udviklingsprogrammet
-
programmet skal under alle omstændigheder laves - efterhånden er der blevet råbt ulv så mange gange om opkøb, så man er blevet lidt immun
-
Det er mange penge, en køber skal op med... kurs 300 er lig med 15 mia.
-
Matas har lige overhalt GEN i C20 stillingen - men der er stadig 2,5 måneder tilbage.
-
ja men de ligger da stadig indenfor 20?
-
absolut - det er kun fordi kirkbi handlede for 600 mio. Matas er ikke i nærheden af C20 baseret på daglig volumen
-
-
meget spændende slide, men holder den?
-
By filing for approval on the basis of compelling Phase 2 data, a breakthrough-designated product could potentially come to market approximately 3 years sooner than a drug without the breakthrough designation (Figure 2). - See more at: http://obroncology.com/obrgreen/article/FDAs-New-Breakthrough-Therapy-Designation#sthash.OqBLXcNr.dpuf
-
This year’s edition of the Bispecific Antibody Summit will be held September 24-26 in Boston, USA. Dr. Schuurman’s presentation, entitled Effective Tumor Killing by Bispecific IgG1-Her2XCD3 Antibodies Generated by Controlled Fab-Arm Exchange, is scheduled for 9.00 a.m. (EDT) on September 26.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind